Investigational Azeliragon May Lessen Cognitive Decline in Mild Alzheimer’s Disease Patients with Type 2 Diabetes, Analysis Finds

Investigational Azeliragon May Lessen Cognitive Decline in Mild Alzheimer’s Disease Patients with Type 2 Diabetes, Analysis Finds
The investigational therapy azeliragon decreased inflammation and lessened cognitive decline and dementia in patients with mild Alzheimer’s disease and type 2 diabetes, compared with a placebo, according to data from a subgroup analysis of the Phase 3 STEADFAST study. The findings were described in the presentation, “Inflammatory Biomarkers, Brain Volumetric MRI, FDG-PET results in Patients with Diabetes in Azeliragon Phase 3 trial in mild Alzheimer’s Disease,” during the 14th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, March 26-31, in Lisbon, Portugal. Previous studies have found that people with type 2 diabetes are more likely to develop Alzheimer's disease. There are more than 400 million people with diabetes around the world who are at a higher risk of developing dementia. Azeliragon is a small investigational molecule, developed by vTv Therapeutics, that inhibits a receptor protein thought to be involved in the development of Alzheimer's, called the receptor for advanced glycation endproducts, or RAGE. Binding of RAGE to its partner proteins, such as the advanced glycation endproduct (AGE), triggers a state of inflammation that can eventually lead to Alzheimer’s disease. Azeliragon binds to RAGE and prevents
Subscribe or to access all post and page content.